Lion Point Capital, LP Tg Therapeutics, Inc. Transaction History

Lion Point Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $9.06 Million - $23.7 Million	-1,160,307 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $4.88 Million - $11.4 Million	321,179 Added 38.28%	1,160,307 $22 Million
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $5.01 Million - $9.3 Million	230,000 Added 37.76%	839,128 $27.9 Million
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $29.9 Million - $39 Million	-718,606 Reduced 54.12%	609,128 $29.4 Million
Q3 2020 Nov 16, 2020	BUY	$18.49 - $27.24 $7.95 Million - $11.7 Million	429,935 Added 47.89%	1,327,734 $35.5 Million
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $7.99 Million - $19.6 Million	897,799 New	897,799 $17.5 Million

338

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.37B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Lion Point Capital, LP with notifications on news.